QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paleologos, N. A. Articles by Cairncross, J. G. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

Treatment of oligodendroglioma: An update

Evanston Northwestern Healthcare, Evanston, IL 60201 [N.A.P.]; London Regional Cancer Centre, London, Ontario, Canada N6A 4L6 [J.G.C.]

¹ Address correspondence and reprint requests to Nina A. Paleologos, MD, Division of Neurology, Evanston Hosptial, 2650 Ridge Avenue, Evanston, IL 60201.

Abstract

Oligodendrogliomas are rare primary brain tumors. Significant attention has recently been focused on these interesting neoplasms because of their unique chemosensitivity and the durability of some of these responses. Surgery and radiation continue to play important roles in the treatment of oliogodendrogliomas. Molecular genetic analyses have given new insight into the allelic deletions that distinguish these tumors and their progression from indolent to more aggressive forms. In the future, molecular genetic analysis may guide therapeutic decisions concerning patients with oligodendroglioma and may help us learn more about how to best treat other malignant brain neoplasms.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. S. Nielsen, H. C. Christensen, M. Kosteljanetz, and C. Johansen Incidence of and survival from oligodendroglioma in Denmark, 1943-2002 Neuro-oncol, January 1, 2009; 11(3): 311 - 317. [Abstract] [Full Text] [PDF]

				M. Brada, L. Viviers, C. Abson, F. Hines, J. Britton, S. Ashley, S. Sardell, D. Traish, A. Gonsalves, P. Wilkins, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas Ann. Onc., December 1, 2003; 14(12): 1715 - 1721. [Abstract] [Full Text] [PDF]

				C. Hong, A. W. Bollen, and J. F. Costello The Contribution of Genetic and Epigenetic Mechanisms to Gene Silencing in Oligodendrogliomas Cancer Res., November 15, 2003; 63(22): 7600 - 7605. [Abstract] [Full Text] [PDF]

				R. E. McLendon, C. J. Wikstrand, M. R. Matthews, R. Al-Baradei, S. H. Bigner, and D. D. Bigner Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor J. Histochem. Cytochem., August 1, 2000; 48(8): 1103 - 1110. [Abstract] [Full Text]

				G. N. Fuller, C. H. Rhee, K. R. Hess, L. S. Caskey, R. Wang, J. M. Bruner, W. K. A. Yung, and W. Zhang Reactivation of Insulin-like Growth Factor Binding Protein 2 Expression in Glioblastoma Multiforme: A Revelation by Parallel Gene Expression Profiling Cancer Res., September 1, 1999; 59(17): 4228 - 4232. [Abstract] [Full Text] [PDF]

				S. H. Bigner, M. R. Matthews, B. K. A. Rasheed, R. N. Wiltshire, H. S. Friedman, A. H. Friedman, T. T. Stenzel, D. M. Dawes, R. E. McLendon, and D. D. Bigner Molecular Genetic Aspects of Oligodendrogliomas Including Analysis by Comparative Genomic Hybridization Am. J. Pathol., August 1, 1999; 155(2): 375 - 386. [Abstract] [Full Text] [PDF]